AI Article Synopsis
- Fibroblast growth factors (FGFs) and their receptors (FGFRs) are important for how cells grow and how new blood vessels form. When these systems don't work properly, it can lead to cancer.
- Researchers are exploring the idea of using FGFR inhibitors (which block FGFR) together with immunotherapy (a type of treatment that helps the immune system fight cancer) to make treatments more effective.
- The study looks at how FGFs and FGFRs influence the environment around tumors and how combining FGFR inhibitors with immunotherapy could help patients with certain types of cancer respond better to treatment.
Article Abstract
Background: Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targeted FGF/FGFR signaling for cancer therapy and several FGFR inhibitors have promising results in different tumors but treatment efficiency may still be improved. The clinical use of immune checkpoint blockade (ICB) has resulted in sustained remission for patients. MAIN: Although there is limited data linking FGFR inhibitors and immunotherapy, preclinical research suggest that FGF/FGFR signaling is involved in regulating the tumor microenvironment (TME) including immune cells, vasculogenesis, and epithelial-mesenchymal transition (EMT). This raises the possibility that ICB in combination with FGFR-tyrosine kinase inhibitors (FGFR-TKIs) may be feasible for treatment option for patients with dysregulated FGF/FGFR signaling.
Conclusion: Here, we review the role of FGF/FGFR signaling in TME regulation and the potential mechanisms of FGFR-TKI in combination with ICB. In addition, we review clinical data surrounding ICB alone or in combination with FGFR-TKI for the treatment of FGFR-dysregulated tumors, highlighting that FGFR inhibitors may sensitize the response to ICB by impacting various stages of the "cancer-immune cycle".
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039534 | PMC |
| http://dx.doi.org/10.1186/s12943-023-01761-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decoding FGF/FGFR Signaling: Insights into Biological Functions and Disease Relevance.
Biomolecules
December 2024
Cell and Molecular Biology Program, University of Arkansas, Fayetteville, AR 72701, USA.
Fibroblast Growth Factors (FGFs) and their cognate receptors, FGFRs, play pivotal roles in a plethora of biological processes, including cell proliferation, differentiation, tissue repair, and metabolic homeostasis. This review provides a comprehensive overview of FGF-FGFR signaling pathways while highlighting their complex regulatory mechanisms and interconnections with other signaling networks. Further, we briefly discuss the FGFs involvement in developmental, metabolic, and housekeeping functions.
View Article and Find Full Text PDFStructure-activity relationship studies of Imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine derivatives to develop selective FGFR inhibitors as anticancer agents for FGF19-overexpressed hepatocellular carcinoma.
Eur J Med Chem
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, 16419, South Korea. Electronic address:
Article Synopsis
- - The activation of FGF and FGFR pathways can lead to cancer, specifically hepatocellular carcinoma (HCC), prompting the development of targeted therapies.
- - Researchers created a new series of compounds, specifically imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine, designed to inhibit FGFRs 1-4, with compound 7n showing the best effectiveness as an FGFR inhibitor.
- - Compound 7n demonstrated strong activity against FGFR1, 2, and 4, had a suitable pharmacokinetic profile, and proved to be effective in reducing tumors in human liver cancer mouse models.
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.
Mol Cancer
November 2024
Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, P. R. China.
Fibroblast growth factors (FGFs) and their receptors regulate numerous cellular processes, such as metabolism and signal transduction, but can also drive tumorigenesis. Specifically, in lung cancer, the overexpression of FGFs, as well as the amplification, mutation and fusion of FGFR genes, are closely linked to the initiation, progression and resistance of the disease, suggesting that targeting FGF/FGFR is an attractive therapeutic strategy for lung cancer treatment. Nintedanib, a multitarget tyrosine kinase inhibitor (TKI) used in combination with docetaxel, has shown some success as a second-line therapy for lung cancer.
View Article and Find Full Text PDFDietary supplementation with N-acetyl-L-cysteine ameliorates hyperactivated ERK signaling in the endometrium that is linked to poor pregnancy outcomes following ovarian stimulation in pigs.
J Anim Sci Biotechnol
November 2024
Frontiers Science Center for Molecular Design Breeding (MOE), State Key Laboratory of Animal Biotech Breeding, Key Laboratory of Animal Genetics, Breeding and Reproduction of the Ministry of Agriculture and Rural Affairs, National Engineering Laboratory for Animal Breeding, College of Animal Science and Technology, China Agricultural University, Beijing, 100193, People's Republic of China.
Article Synopsis
- - Exogenous gonadotropin ovarian stimulation is crucial for managing reproduction in animals but has been linked to lower pregnancy rates and fewer piglets born, despite increased estradiol (E) levels.
- - High E levels negatively impact uterine receptivity by overactivating specific signaling pathways that lead to excessive growth of endometrial cells, thereby reducing pregnancy success.
- - Supplementing N-acetyl-L-cysteine (NAC) in the diet improves uterine receptivity and enhances pregnancy rates and piglet counts in gilts following ovarian stimulation.
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.
J Exp Clin Cancer Res
November 2024
Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
Among blood cancers, multiple myeloma (MM) represents the second most common neoplasm and is characterized by the accumulation and proliferation of monoclonal plasma cells within the bone marrow. Despite the last few decades being characterized by the development of different therapeutic strategies against MM, at present such disease is still considered incurable. Although MM is highly heterogeneous in terms of genetic and molecular subtypes, about 67% of MM cases are associated with abnormal activity of the transcription factor c-Myc, which has so far revealed a protein extremely difficult to target.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!